icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
eNrlWE1z2jAQvfMrGO6ysSF8dAyZliYtM8mUkjDt9MIIeQ2iQnL0AaS/vjImLemYphHxpbkwRpLfrqW3b3cVnW9XrLoGqajgvVrg1WtV4ETElM97tcntJerUzvuVaInX+GBZ26t7QVirEoaV6tWyWW8GmCvv6/XVe7Dvg6z1K9VIzJZA9KN1RlPmfcRqcY3TbE01WgsaV1egFyLu1VKjd6PVSGlpvehvhPyuUkwg8vcjh7PLafNwPPIzsH9ANQrkFebzQlDgTpjESAlcD7CGuZD3hdCpjINp2O20gm7HyQhVY1DCSAIjrBcjKdY0hrjQVoKZAicjySa+AblmoDMjheD+kqyUEzhe4u0Y7obFTr+1swO91aiOgnar2203W4120AmcTMmDrSqmj/0IP502Gt16Kwh94H4MhGYsRzyshyGqN5tnfkx8BSsUGxQ2ERdrWM0koN28HSOCMZgDigExjBbYaED2R0iqd4MKc/uQCqntA5KQGLVfG8MKc/sYI0wIKJRKGzrkAUml1hXMMhQNxBJL0jtHyowy46wkslA1eEz8kuxIuHuSlDFVKcP33lKlrluFJbbTIK08lfch2RfcSiuYzO7ZH/jcMOY/0+vJXs5K8jhTy4EwloLFqnY5dt2IgbDBsT1+om5CrLd7LlJQLwf7Q/DiJDQyM0aJq9JaLTSg9GQ8PC60r0Cj3mEFE1meSH2hPBYb9fLid0i2krzfHQx7oqA4O3OO7W+W2Ufy8YWRIgXfyiJVp6jdkCfiVJ2zwVIM9RAq/3uU7KpWQTCDI3UrclRiGx4PZXZpAVhecOcThaAfLm5dWfvZgLy/2f0thKZx7xff3NJUGbnPxshRx58fcbnw/LWjScg07LSbnYZbP2Nksa4ttE7VG9/fbDbeAqs89rxEvpZ0eFAYldfklVJ95dVonlJKcn2W1wrPI46rDjxVn53ac+zf3/c2hTa0NHDCWeQpozRhH168fK743XCU5vbokbaVZ2bXHGBtBaqs6tDMikvDk7KTPVd+Ka1AfEoSeuT27SgvIz+/+etXIj+79etXfgLSrbw1
7bajKzgnGBrvuvjF
Listen
